MedTrace Logo

Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

NCT00403156 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-12-31

No results posted yet for this study

Summary

The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.

Conditions

  • Choroidal Neovascularization

Interventions

DRUG

Imatinib Mesylate /Ranibizumab

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Vitreous -Retina- Macula Consultants of New York

    lead OTHER

Principal Investigators

  • Richard F. Spaide, M.D. · Vitreous Retina Macula Consultants of New York, P.C.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
51 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00403156 on ClinicalTrials.gov